SANCTURA Drug Patent Profile
✉ Email this page to a colleague
When do Sanctura patents expire, and what generic alternatives are available?
Sanctura is a drug marketed by Allergan and is included in two NDAs.
The generic ingredient in SANCTURA is trospium chloride. There are sixteen drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the trospium chloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sanctura
A generic version of SANCTURA was approved as trospium chloride by GLENMARK GENERICS on August 13th, 2010.
Summary for SANCTURA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 70 |
| Clinical Trials: | 8 |
| Patent Applications: | 1,557 |
| DailyMed Link: | SANCTURA at DailyMed |
Recent Clinical Trials for SANCTURA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Neil M. Resnick | Phase 4 |
| National Institute on Aging (NIA) | Phase 4 |
| Karuna Therapeutics | Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for SANCTURA
US Patents and Regulatory Information for SANCTURA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan | SANCTURA | trospium chloride | TABLET;ORAL | 021595-001 | May 28, 2004 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Allergan | SANCTURA XR | trospium chloride | CAPSULE, EXTENDED RELEASE;ORAL | 022103-001 | Aug 3, 2007 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
